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Abstract 
Background: Muscle wasting negatively impacts the progress of chronic diseases such as lung cancer (LC) and 
emphysema, which are in turn interrelated.
Objectives: We hypothesized that muscle atrophy and body weight loss may develop in an experimental mouse 
model of lung carcinogenesis, that the profile of alterations in muscle fiber phenotype (fiber type composition and 
morphometry, muscle structural alterations, and nuclear apoptosis), and in muscle metabolism are similar in both 
respiratory and limb muscles of the tumor‑bearing mice, and that the presence of underlying emphysema may influ‑
ence those events.
Methods: Diaphragm and gastrocnemius muscles of mice with urethane‑induced lung cancer (LC‑U) with and with‑
out elastase‑induced emphysema (E–U) and non‑exposed controls (N = 8/group) were studied: fiber type composi‑
tion, morphometry, muscle abnormalities, apoptotic nuclei (immunohistochemistry), and proteolytic and autophagy 
markers (immunoblotting) at 20‑ and 35‑week exposure times. In the latter cohort, structural contractile proteins, 
creatine kinase (CK), peroxisome proliferator‑activated receptor (PPAR) expression, oxidative stress, and inflammation 
were also measured. Body and muscle weights were quantified (baseline, during follow‑up, and sacrifice).
Results: Compared to controls, in U and E–U mice, whole body, diaphragm and gastrocnemius weights were 
reduced. Additionally, both in diaphragm and gastrocnemius, muscle fiber cross‑sectional areas were smaller, struc‑
tural abnormalities, autophagy and apoptotic nuclei were increased, while levels of actin, myosin, CK, PPARs, and 
antioxidants were decreased, and muscle proteolytic markers did not vary among groups.
Conclusions: In this model of lung carcinogenesis with and without emphysema, reduced body weight gain and 
muscle atrophy were observed in respiratory and limb muscles of mice after 20‑ and 35‑week exposure times most 
likely through increased nuclear apoptosis and autophagy. Underlying emphysema induced a larger reduction in the 
size of slow‑ and fast‑twitch fibers in the diaphragm of U and E–U mice probably as a result of the greater inspiratory 
burden imposed onto this muscle.
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Background
Skeletal muscle dysfunction and wasting are common 
features of patients with chronic respiratory conditions 
and cancer [1–4]. These frequently occurring systemic 
manifestations impact the patients’ exercise capac-
ity leading to the development of early fatigue [1–5]. 
Cachexia, characterized by severe body and muscle mass 
loss and systemic inflammation, negatively impacts the 
quality of life of the patients and is usually present in 
advanced stages of their disease. In animal models of 
cachexia and muscle wasting of different etiology (res-
piratory, cardiac and cancer-induced cachexia), similar 
features to those observed in patients have also been 
reported [6–11].
Recent evidence reported by our group and others [3, 
4, 6–20] has shown that several cellular and molecular 
mechanisms are clearly involved in the pathophysiology 
of muscle mass loss in patients with muscle wasting [3, 
4, 16–20], as well as in different experimental models 
of cachexia [6–15]. The most relevant mechanisms are 
part of a cascade of events that lead to enhanced mus-
cle protein breakdown [4, 16, 18], through several cellular 
signaling pathways [4, 16, 18], mitochondria respiratory 
chain dysfunction [6, 10, 14, 19, 21–23], systemic inflam-
mation [4, 5, 24], muscle and systemic oxidative stress 
[4, 6, 16, 25–27], apoptosis [7], and autophagy [4, 28]. 
Moreover, in patients with chronic obstructive pul-
monary disease (COPD) and lung cancer (LC) [4, 24], 
landmark structural and ultrastructural abnormalities 
(sarcomere disruptions) were also demonstrated in the 
vastus lateralis, which were associated with a significant 
myosin heavy chain (MyHC) loss in those muscles [4, 17]. 
Moreover, in COPD patients including a few with muscle 
mass loss, the diaphragm [17, 29, 30] has been consist-
ently less severely affected than the lower limb muscles, 
in which significant signs of atrophy and proteolysis have 
been reported [4, 16, 18, 20, 23, 25–27, 31]. Nonetheless, 
we previously showed that in mice with elastase-induced 
emphysema, a well-validated model of chronic emphy-
sema [9, 32–34], more prominent signs of muscle mass 
and MyHC loss were observed in the diaphragm than in 
the limb muscle.
Patients with either COPD- or LC-associated cachexia 
exhibited similar molecular and cellular features related 
to muscle mass loss in their vastus lateralis and blood 
[4]. In fact, the study was aimed to demonstrate that the 
late events taking place in the skeletal muscle of patients 
with cachexia of respiratory etiology (either COPD or 
LC) shared similar molecular and cellular profiles regard-
less of the underlying condition [4]. On the other hand, 
it has also been repeatedly demonstrated that COPD per 
se, especially lung emphysema, is a major risk factor for 
LC and that the two conditions often coexist in the same 
patients [35–41]. Thus, more severe muscle wasting may 
occur in patients with LC and underlying emphysema.
Importantly, the experimental models of cachexia in 
which the underlying biological mechanisms have been 
identified so far were mostly characterized by a subacute 
exposure of the animals to a large burden of different 
cancer cell types that led to a rapid muscle mass loss with 
implications in total body weight [7, 8, 14, 42]. Whether 
similar features in skeletal muscles are to be expected in a 
chronic model of lung carcinogenesis, which may mimic 
more closely the human disease, remains to be answered. 
Also, identification of whether the expression of biologi-
cal events involved in muscle metabolism that maintain 
muscle mass may vary throughout time in wasted mus-
cles of experimental cachexia remains an open question. 
Besides, the analysis of the main respiratory muscle, the 
diaphragm, will also be of interest in order to elucidate 
the potential contribution of local (lung disease) and sys-
temic factors.
On the basis of this, we hypothesized that muscle atro-
phy and body weight and muscle mass loss may also 
develop in an experimental model of lung carcinogenesis. 
Furthermore, it was also hypothesized that the profile 
of structural and molecular events involved in protein 
metabolism and muscle mass maintenance are similar 
in both respiratory and limb muscles of mice chronically 
exposed to lung carcinogenesis (airways and lungs) for 
several relatively long periods of time in order to mimic 
the human condition (intermediate and late time-points). 
Finally, we also sought to identify whether the pres-
ence of underlying emphysema may influence the pat-
tern of expression of the muscle biological features and 
mass loss in the tumor-bearing animals. Accordingly, 
two different experimental models were established: 
lung carcinogenesis with and without emphysema in 
mice. Hence, the study objectives were that in diaphragm 
and gastrocnemius of mice with urethane-induced LC 
Keywords: Lung carcinogenesis‑induced muscle mass loss, Underlying emphysema, Respiratory and limb muscle 
atrophy and structural abnormalities, Muscle apoptotic nuclei, Muscle‑specific proteins, PPARs proteolytic and 
autophagy markers
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with and without emphysema (elastase), the following 
markers were explored at two different time-points (20 
and 35  weeks): (1) muscle fiber type and morphometry 
(sizes), (2) structural abnormalities including the num-
ber of apoptotic nuclei, (3) muscle-specific structural 
and functional proteins, (4) metabolic signaling factors, 
(5) proteolytic and autophagy markers, and (6) redox bal-
ance and inflammation. Furthermore, non-exposed con-
trol groups of mice were also used for the purpose of the 
investigation, and body and muscle weights were evalu-
ated at baseline and at the end of the study period in all 
the groups and cohorts of mice.
Methods
(See also the online supplementary information (Addi-
tional file 1) for detailed information on all the method-
ologies used in the study).
Animal experiments
Experimental design
Forty-eight male A/J strain mice (2-months old, 16–23 g) 
were used for the purpose of the investigation, which 
were randomly divided into two independent time-
cohorts: 20 and 35  weeks. Animals were further sub-
divided into the following groups in each time-cohort 
(N  =  8/group): (1) non-exposed control mice, (2) lung 
carcinogenesis mice induced by urethane (U group), and 
(3) lung emphysema-carcinogenesis mice induced by 
elastase and urethane (E–U group). Lung carcinogenesis 
was induced as a result of a single intraperitoneal injec-
tion of 1  mg/g urethane (Urethane U2500 Sigma, St. 
Louis, Missouri, USA). Lung emphysema was induced 
through a single oropharyngeal instillation of six units 
per 30 g body weight of porcine pancreatic elastase (PPE, 
EC134GI, EPC, MI, USA) 0.15  mg/100  g elastase-high 
purity (EC134GI, Elastin Products Company, Owensville, 
Missouri, USA), following previously reported method-
ologies [9, 32].
Cancer and emphysema induction protocols
Briefly, after administration of 2 % isoflurane in an induc-
tion box, the animals were placed on a ramp with an 
angle of 60°. Once immobilized, the volume of elastase 
was deposited in their mouth. The nostrils were occluded 
to force breathing through the mouth, thus enabling the 
mice to inhale the solution. After aspiration, the animals 
rested on the ramp for a few seconds to let them recover 
the normal breathing. Animals exposed to both emphy-
sema and lung carcinogenesis received an oropharyngeal 
instillation of elastase on day 0 together with a single 
intraperitoneal injection of urethane on day 9 (Fig.  1a). 
The lung carcinogenesis group (U) received an oro-
pharyngeal instillation of saline solution on day 0 and 
a single intraperitoneal injection of urethane on day 9 
(Fig.  1b). Control groups were followed up for 20 or 
35  weeks depending on the experimental time-cohort. 
These animals received oropharyngeal or intraperito-
neal injections of saline solutions (0.1 mL) on days 0 or 9, 
respectively (Fig. 1c), as also described in previous inves-
tigations [9, 32, 34]. The different times-cohorts (20- and 
35-weeks) started on day 9 after the urethane or saline 
(controls) injection in all the study groups.
This study was designed in accordance with the ethi-
cal regulations on animal experimentation (EU 2010/63 
CEE, Real Decreto 53/2013 BOE 34, Spain) at the Center 
for Applied Medical Research (CIMA), and the Dec-
laration of Helsinki for the use and care of animals for 
research purposes. Ethical approval was obtained by the 
Animal Experimentation Ethics Committee of CIMA in 
Pamplona (Spain), where the animal experiments were all 
conducted.
In vivo measurements conducted on the animals
Water and food were administered to the animals for the 
entire duration of the study and they remained under 
housing environmental conditions in a 12:12 light–dark 
cycles. In all the mice, body weight was determined on 
day 0 before treatment administration and at 4- and 
14-week time points, and immediately prior to their sac-
rifice at either 20- or 35- week time-points in each cohort 
[9, 32]. The percentage of body weight gain at the end of 
the study period was calculated as follows: [(body weight 
on either week 35 or 24 − body weight on day 0)]/body 
weight on day 0  ×  100. Additionally, the percentage of 
muscle mass relative to final body weight in each animal 
was calculated as follows: [(muscle mass weight/final 
body weight) × 100].
Micro‑computer tomography (CT)
Prior to sacrifice, animals underwent CT scan analyses 
from their lungs, which were used to verify the presence 
of the emphysema with and without the tumors follow-
ing previously reported methodologies [32, 34]. Before 
the scan, animals were intraperitoneally anaesthetized 
prior to intubation, to be then connected to a Flexivent 
rodent ventilator (Scireq, Montreal, Canada). Animals 
were kept alive (breathing), under anesthesia (2 % isoflu-
rane) until complete relaxation was reached. During the 
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scan analyses, 0.5  % isoflurane was administered to the 
mice. All mice were scanned with an X-ray micro-CT 
(Micro-CAT II, Siemens Pre-Clinical Solutions, Knox-
ville, Tennessee, USA), with a source 80 voltage kV and 
a 500 microA current. Seven hundred micro-CT projec-
tions were acquired during isopressure breaths, which 
were hold for 650 ms (450 ms-exposure time/projection). 
A commercially available Dose Calculator software (Sie-
mens Pre-clinical Solutions, Knoxville, Tennessee, USA) 
was used to estimate X-ray dosage-computed. In the cur-
rent investigation, specific measurements of the degree of 
emphysema were not carried out in the animals as these 
analyses had been conducted in previously published 
studies and the model was extremely reproducible [32–
34, 43].
Prior to sacrifice an intraperitoneal injection of 90 mg/
kg ketamine (Imalgène®, Merial, Lyon, France) and 
10  mg/kg xylazine (Rompun®, Bayer AG, Leverkusen, 
Germany) was administered. In all cases, the pedal and 
blink reflexes were evaluated in order to verify total 
anesthesia depth. Animals were exsanguinated to facili-
tate removal or organs and skeletal muscles. Immedi-
ately afterwards, in all groups of mice, the lungs, the 
diaphragm and gastrocnemius muscles were obtained: 
gastrocnemius was obtained in the first place while the 
animals were still breathing, subsequently to collect the 
diaphragm and lungs while the mice were still alive as 
conducted in previous studies [7–9, 32]. All muscle spec-
imens of the 20-week cohort were immersed in buffered 
4 % formaldehyde for 24 h and washed in several alcohol 
Fig. 1 a Graphical time‑line representation of the elastase–urethane group of mice. b Graphical time‑line representation of the urethane group of 
animals. c Graphical time‑line representation of the control group of rodents
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steps prior to paraffin-embedding. In the 35-week cohort 
of animals, the muscles, which were of larger size, were 
split in two samples, one of which was also immediately 
fixed in 4 % formaldehyde, rinsed in alcohols and embed-
ded in paraffin, and the rest of the tissue was immediately 
frozen in liquid nitrogen to be subsequently preserved at 
−80 °C until further use. Paraffin-embedded tissues were 
used to analyze the histological features of tumors in the 
lungs, while in the muscles, fiber types, potential struc-
tural abnormalities, and apoptotic nuclei counts were 
determined. Moreover, frozen muscle specimens were 
used for immunoblotting and enzyme-linked immunoab-
sorbent assay (ELISA) procedures.
Molecular biology analyses
All biological analyses were performed in the same lab-
oratory at IMIM-Hospital del Mar (Barcelona, Spain) 
except for the lung histological analyses that were per-
formed at CIMA (Pamplona, Spain).
Histological analyses of the lungs
Lung carcinogenesis histology was evaluated on 3 μm par-
affin-embedded sections of the lungs in U and E–U groups 
of mice, according to previously published methodologies 
[32–34, 43]. Lobe sections were stained with hematoxy-
lin and eosin (H&E). Images of the sections were taken at 
50× and 200× under light microscopy (Zeis Axioplan 2ie 
microscope, Carl Zeiss, Jena, Germany).
Muscle fiber counts and morphometry
Diaphragm and gastrocnemius muscle fibers were iden-
tified on 3  μm thick paraffin-embedded sections in all 
groups of mice and the two time-cohorts. MyHC-I and 
MyHC-II isoforms were identified using anti-MyHC-I 
(clone MHC, Biogenesis Inc., Poole, England, UK) and 
anti-MyHC-II antibodies (clone MY-32, Sigma, Saint 
Louis, MO), respectively, according to previously pub-
lished methodologies [4, 6–8, 18].
Muscle structural abnormalities
The area fraction of normal and abnormal muscle was 
evaluated on 3  μm paraffin-embedded sections of the 
diaphragm and gastrocnemius muscles in all groups of 
mice following previously published methodologies [4, 
6–8, 16].
Terminal deoxynucleotidyl transferase‑ mediated uridine 
5′‑triphosphate (UTP) nick‑ end labelling (TUNEL) assay
In muscle paraffin-embedded sections, apoptotic nuclei 
were identified using the TUNEL assay (In Situ Cell 
Death Detection Kit, POD, Roche Applied Science, 
Mannheim, Germany) in both diaphragm and gastroc-
nemius muscle specimens from all study groups follow-
ing the manufacturer’s instructions and previous studies 
[6–8, 44]. In each muscle preparation, altered fibers were 
expressed as the ratio of total TUNEL positively-stained 
nuclei to the total number of counted nuclei, as also pre-
viously described [6–8, 44]. A minimum amount of 300 
nuclei were counted in each muscle preparation. Final 
results corresponded to the mean value of the counts 
provided by the two independent observers (concordance 
rate 95 %).
Immunoblotting of 1D electrophoresis
Protein levels of the different molecular markers explored 
in the study muscles were analyzed in the diaphragm and 
gastrocnemius of the experimental groups belonging to 
the 35-week cohort using previously published method-
ologies [6–8, 44]. Protein content of the different mark-
ers was identified using specific primary antibodies: actin 
(anti-alpha-sarcomeric actin antibody, clone 5C5, Sigma 
Sigma-Aldrich, St. Louis, MO, USA), myosin heavy chain 
(anti-MyHC antibody, clone A4.1025, Upstate-Millipore, 
Temecula, CA, USA), creatine kinase (anti-creatine kinase 
antibody, Santa Cruz), carbonic anhydrase-3 (anti-car-
bonic anhydrase-3 antibody, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), myogenin (anti-myogenin anti-
body, Santa Cruz), catalase (anti-catalase antibody, Cal-
biochem, Darmstadt, Germany), superoxide dismutase 
(SOD)2 (anti-SOD2 antibody, Santa Cruz), SOD1 (anti-
SOD1 antibody, Santa Cruz), malondialdehyde (MDA) 
protein adducts (anti-MDA protein adducts antibody 
Academy Bio-Medical Company, Inc., Houston, TX, 
USA), peroxisome proliferator-activated receptor (PPAR)-
alpha (anti-PPAR-alpha antibody (H-98), Santa Cruz), 
PPAR-gamma (anti- PPAR-gamma antibody (H-100), 
Santa Cruz), PPAR gamma coactivator (PGC) -1α (anti-
PGC-1 alpha antibody (H-300), Santa Cruz), total protein 
ubiquitination (anti-protein ubiquitination antibody, Bos-
ton Biochem, Cambridge, MA, USA), ubiquitin-conjugat-
ing enzyme E214k (anti-E214K antibody, Boston Biochem), 
muscle ring finger (MURF)-1 (anti-MURF-1 antibody, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), cal-
pain-1 (anti-calpain-1 antibody, Cell Signaling, USA), 
nucleoporin p-62 (anti-p62/SQSTM1 antibody, Sigma-
Aldrich, St. Louis, MO, USA), beclin-1 (anti-beclin-1 
antibody, Santa Cruz), light chain (LC)3B (anti-LC3B anti-
body, Cell Signaling, Boston, MA, USA), and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH, anti-GAPDH 
antibody, Santa Cruz). Antigens from all the samples 
were detected using horseradish peroxidase (HRP)-con-
jugated secondary antibodies (Jackson ImmunoResearch 
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Inc, West Grove, PA, USA) and a chemiluminescence kit 
(Thermo Scientific, Rockford, IL, USA).
Cytokine ELISA
Protein levels of the inflammatory cytokines tumor 
necrosis factor (TNF)-α and interleukin (IL)-6 were 
quantified in the diaphragm and gastrocnemius muscles 
in all study groups of the 35-week cohort using specific 
sandwich ELISA kits (eBioscience, Bender MedSystems 
GmbH, Vienna, Austria), and specific manufacturer’s 
instructions and previous studies were followed [4, 6, 25, 
26].
Statistical analysis
The normality of the study variables was verified using 
the Shapiro–Wilk test. Physiological and biological 
results are represented as mean (standard deviation) 
and the comparisons between all study groups were ana-
lyzed using the one-way analysis of variance (ANOVA), 
in which Tukey post hoc analysis was used to adjust for 
multiple comparisons among the three study groups in 
each time-cohort (20 and 35  weeks) independently. For 
the purpose of the investigation, results obtained in the 
animals and those obtained in the study muscles were 
subsequently analyzed as follows: (1) non-exposed con-
trols versus lung carcinogenesis mice (U group), (2) 
non-exposed controls versus lung emphysema-carcino-
genesis mice (E–U group), and (3) U versus E–U groups 
of animals. The sample size chosen was based on previous 
studies [6–9, 11, 14, 45, 46] and on assumptions of 80 % 
power to detect an improvement of more than 20  % in 
measured outcomes at a level of significance of p ≤ 0.05. 
In most biological variables, mean difference between 
groups was initially estimated at a minimum of 20–25 % 
and standard deviation was approximately 25–30 % of the 
mean value for each of the variables. All statistical analy-
ses were performed using the Statistical Package for the 
Social Sciences (Portable SPSS, PASW statistics 12.0 ver-
sion for windows, SPSS Inc., Chicago, IL, USA).
Table 1 Physiological characteristics of  all study groups 
of mice
Variables are presented as mean (standard deviation)
U urethane, E–U elastase–urethane, g gram
Statistical significance: * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 between any of 
the experimental groups and the control mice




 Initial body weight (g) 18.7 (0.67) 19.4 (1.91) 18.7 (1.55)
 Final body weight (g) 26.2 (1.38) 24.5 (2.18) 21.9 (1.50)***,§
 Body weight gain (%) +39.8 (6.58) +26.3 (5.46)* +17.8 (10.8)***
 Diaphragm weight (g) 0.08 (0.01) 0.06 (0.004)*** 0.06 (0.01)***
 Diaphragm (% body 
weight)
0.30 (0.05) 0.25 (0.02)* 0.26 (0.04)
 Gastrocnemius weight 
(g)
0.15 (0.004) 0.12 (0.01)*** 0.12 (0.01)***
 Gastrocnemius (% 
body weight)
0.56 (0.04) 0.50 (0.04) 0.55 (0.05)
35 weeks
 Initial body weight (g) 18.7 (0.67) 19.6 (1.61) 18.9 (2.71)
 Final body weight (g) 29.4 (2.22) 27.4 (1.41) 22.3 (2.54)***, §§
 Body weight gain (%) +56.9 (10.1) +39.9 (8.40)* +18.1 (5.45)***, §
 Diaphragm weight (g) 0.09 (0.02) 0.06 (0.01)** 0.06 (0.01)**
 Diaphragm (% body 
weight)
0.30 (0.04) 0.22 (0.04)* 0.28 (0.05)
 Gastrocnemius weight 
(g)
0.15 (0.01) 0.10 (0.02)*** 0.10 (0.01)***
 Gastrocnemius (% 
body weight)
0.50 (0.03) 0.37 (0.07)** 0.47 (0.07)§
Fig. 2 a Graphical representation of the progression of body 
weight in mice from all experimental groups over the study period 
in the 20‑week time‑cohort. The following signs have been used in 
each group: control (diamonds), U group (squares), and E–U group 
(triangles). b Graphical representation of the progression of body 
weight in mice from all experimental groups over the study period 
in the 35‑week time‑cohort. The following signs have been used in 
each group: control (diamonds), U group (squares), and E–U group 
(triangles). E–U elastase–urethane, U urethane
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Results
Physiological characteristics
As shown in Table 1 and Fig. 2, body weight at the end of 
study period (20- and 35-time-points) was significantly 
reduced in E–U mice compared to non-exposed con-
trols in both time-cohorts. Nonetheless, body weight 
gain was significantly reduced in both U and E–U 
groups compared to the non-exposed controls in each 
time-cohort (Table  1). Diaphragm and gastrocnemius 
muscle weights were significantly reduced in U and 
E–U groups compared to non-exposed control ani-
mals in both 20-week and 35-week cohorts (Table  1). 
However, compared to control animals, the percentage 
of diaphragm weight to total body weight significantly 
decreased only in U mice of both time-cohorts, whereas 
in the gastrocnemius, a significant reduction in this 
parameter was observed only in U mice of the 35-week 
cohort (Table 1).
Fig. 3 Representative images of micro‑CT scan analyses in all study groups in the 20‑ (left panel) and 35‑week (right panel) cohorts of mice. Lung 
nodules (orange triangles) are shown in micro‑CT slices of lung parenchyma for U (middle panel) and E–U (bottom panel) groups of mice. E–U 
elastase–urethane, U urethane
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Micro‑CT imaging results
The results obtained from the micro-CT analyses of the 
longitudinal subgroups confirm the feasibility of conduct-
ing in  vivo longitudinal studies of these models in both 
20- and 35-week time-cohorts. In both U and E–U groups 
of mice, the appearance of the nodules, which were iden-
tified as hyper intense convex masses (most of the solid 
structures seen in the CT-images), were found well-cir-
cumscribed, in juxta pleural or juxta vascular areas of the 
lungs (Fig.  3). In both time-cohorts, the intensity of the 
lung parenchyma was lower in E–U (Fig. 3, bottom pan-
els) animals compared to U mice (Fig. 3, middle panels) as 
a result of the lung tissue loss induced by elastase, while 
lung volume distension was observed in the same animals 
(Fig. 3).
Lung histological characteristics
In accordance with the radiological data, histological 
features confirmed the presence of emphysema in all the 
mice that had been treated with elastase (E–U group) 
of both time-cohorts. Namely, the alveolar walls were 
remarkably thin and the alveolar spaces were enlarged 
(Fig. 4). The tumor lesions observed in the U mice (Fig. 4, 
left panels) were histologically similar to those observed 
in the E–U animals (Fig. 4, right panels), with the excep-
tion of the surrounding parenchyma, which was relatively 
normal in the U animals (non-emphysematous lungs, 
Fig. 4, left panels). The lesions were mostly adenomas or 
adenomatous proliferative lesions, a few of them in close 
or direct contact with club cells lining the bronchioles. 
The largest lesions in both groups and cohorts displayed 
Fig. 4 Representative examples of histological sections stained with hematoxylin and eosin (×5 and ×20) of whole individual tumors in U (left 
panels) and E–U (right panels) groups of mice. E–U elastase–urethane, U urethane
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the classical adenocarcinoma phenotype, as shown by 




In the 20- and 35-week cohorts of mice, proportions 
of type I and type II fibers did not significantly differ in 
any muscle among the experimental groups (Tables  2, 
3; Fig.  5a, b). As expected, muscle fiber cross-sectional 
areas were significantly decreased in the diaphragm and 
gastrocnemius muscles of U and E–U mice in both 20- 
and 35-week time cohorts compared to control animals 
(Tables 2, 3; Fig. 5a, b). Atrophy was found in both slow- 
and fast-twitch fibers in both types of muscles. Addi-
tionally, in the diaphragm of E–U mice, the size of type 
I and type II fibers was significantly reduced when com-
pared to U animals in both 20- and 35-week time cohorts 
(Tables 2, 3; Fig. 5a, b). Furthermore, the distributions of 
the muscle fiber cross-sectional areas in respiratory and 
limb muscles of all study groups in both 20- and 35-week 
time-cohorts are depicted in Fig. 6.
Muscle abnormalities
In the 20  week-cohort of mice, a significant increase in 
the proportion of muscle structural abnormalities and 
internal nuclei counts were found in both diaphragm and 
gastrocnemius muscles of U and E–U mice compared 
to non-exposed control animals (Fig. 7a–d). In the same 
cohort, the proportion of inflammatory cell counts was 
only significantly increased in the diaphragm muscle of 
U and E–U mice compared to the non-exposed controls 
(Fig. 7a–d). Interestingly, in the 35-week cohort, propor-
tions of total muscle abnormalities, inflammatory cell 
and internal nuclei counts were significantly higher in 
both muscles of U and E–U mice compared to the non-
exposed controls (Fig. 8a–d).
Table 2 Muscle structure in  both diaphragm and  gastroc-
nemius muscles of mice of the 20-week cohort
Variables are presented as mean (standard deviation)
U urethane, E–U elastase–urethane
Statistical significance: * p ≤ 0.05 and *** p ≤ 0.001 between any of the 
experimental groups and the control mice




 Fiber type proportions
  Type I fibers (%) 8.9 (1.66) 9.5 (1.70) 8.3 (1.05)
  Type II fibers (%) 91.1 (1.66) 90.5 (1.70) 91.7 (1.05)
 Cross‑sectional area
  Type I fibers 
(μm2)
342.7 (61.9) 235.7 (32.5)*** 155.3 (41.5)***, §
  Type II fibers 
(μm2)
473.2 (43.0) 328.2 (30.4)*** 230.6 (50.5)***, §§§
Gastrocnemius
 Fiber type proportions
  Type I fibers (%) 25.1 (7.28) 20.6 (4.82) 20.7 (6.74)
  Type II fibers (%) 74.9 (7.28) 79.4 (4.82) 79.3 (6.74)
 Cross‑sectional area
  Type I fibers, 
(μm2)
746.6 (69.6) 504.5 (123.5)*** 491.4 (47.3)***
  Type II fibers, 
(μm2)
691.4 (65.7) 622.4 (61.8)* 568.5 (31.3)***
Table 3 Muscle structure in  both diaphragm and  gas-
trocnemius muscles of  all groups of  mice of  the 35-week 
cohort
Variables are presented mean (standard deviation)
U urethane, E–U elastase–urethane
Statistical significance: * p ≤ 0.05 and *** p ≤ 0.001 between any of the 
experimental groups and the control mice




 Fiber type proportions
  Type I fibres (%) 8.1 (1.00) 8.2 (0.80) 7.7 (1.05)
  Type II fibres (%) 91.9 (1.00) 91.8 (0.80) 92.3 (1.05)
 Cross‑sectional area
  Type I fibres (μm2) 257.9 (33.1) 221.7 (30.3)* 182.4 (12.8)***, §
  Type II fibres (μm2) 377.9 (30.1) 326.7 (47.6)* 258.8 (28.1)***, §§
Gastrocnemius
 Fiber type proportions
  Type I fibres (%) 22.7 (6.26) 24.0 (4.73) 20.5 (3.25)
  Type II fibres (%) 77.3 (6.26) 76.0 (4.73) 77.5 (3.25)
 Cross‑sectional area
  Type I fibres (μm2) 824.7 (155.2) 680.5 (67.6)* 609.8 (74.6)***
  Type II fibres (μm2) 835.3 (100.7) 721.9 (70.4)* 665.2 (80.0)***
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Muscle fiber apoptosis
A significant rise in TUNEL positively-stained nuclei was 
observed in 20- and 35-week cohorts of mice in both dia-
phragm and gastrocnemius muscles of U and E–U mice 
compared to non-exposed controls (Figs.  9a, b, 10a, b, 
respectively).
Contractile and functional muscle proteins
All the analyses of contractile and functional muscle 
proteins were carried out in the 35-week cohort mice. 
Protein levels of skeletal muscle actin were significantly 
reduced in both diaphragm and gastrocnemius of U mice 
compared to the non-exposed controls, while in the E–U 
group, a significant decline in actin levels was only seen 
in the diaphragm (Fig. 11a; Additional file 1: Figure S3). 
Protein levels of MyHC and creatine kinase decreased 
in both diaphragm and gastrocnemius of U and E–U 
mice compared to the non-exposed controls (Fig. 11b, c; 
Additional file 1: Figures S4, S5). In E–U mice, carbonic 
anhydrase-3 levels were only significantly reduced in 
the diaphragm compared to the non-exposed controls 
(Fig. 11d; Additional file 1: Figure S6).
Muscle growth and metabolism
All the analyses of muscle growth and metabolism were 
carried out in the 35-week cohort mice. Protein levels of 
myogenin were only significantly decreased in the dia-
phragm of E–U mice compared to non-exposed controls 
(Fig. 12a; Additional file 1: Figure S7). In U and E–U mice, 
protein levels of PPAR-α and PPAR-γ were significantly 
decreased in the diaphragm compared to control ani-
mals, and levels of the latter marker was also significantly 
reduced in limb muscle of U and E–U mice compared 
to controls in both time-cohorts (Fig. 12b, c; Additional 
file  1: Figures S8, S9). Protein levels of PGC-1α did not 
significantly differ among the study groups in any of the 
muscles (Fig. 12d; Additional file 1: S10).
Muscle redox balance proteins
All the analyses of muscle redox balance proteins were 
carried out in the 35-week cohort mice. Total MDA-
protein adducts were only significantly increased in the 
gastrocnemius of E–U mice compared to non-exposed 
controls (Fig.  13a; Additional file  1: Figure S11). A sig-
nificant rise in SOD1 levels was also detected in the limb 
Fig. 5 a Representative examples of stained muscle fibers in diaphragm and gastrocnemius muscles of control (top panel), U group (middle panel) 
and E–U group (bottom panel) in the 20‑week cohort of animals. Myofibers positively stained with the anti‑MyHC type II antibody appear in brown 
color (calibration bar 200 μm). Type I fibers appear in white color (not stained). b Representative examples of stained muscle fibers in diaphragm 
and gastrocnemius muscle of control (top panel) and U group (middle panel) and E–U group (bottom panel) in the 35‑week cohort of animals. 
Myofibers positively stained with the anti‑MyHC type II antibody appear in brown color (calibration bar 200 μm). Type I fibers appear in white color 
(not stained). anti-MyHC anti‑myosin heavy chain, E–U elastase–urethane, U urethane
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muscle of both U and E–U groups compared to control 
mice, while no significant differences were detected in 
the diaphragm (Fig.  13b; Additional file  1: S12). How-
ever, SOD2 and catalase protein levels were significantly 
reduced in the gastrocnemius of both U and E–U mice 
compared to non-exposed controls, whereas no signifi-
cant differences were detected in the diaphragm (Fig. 13c, 
d; Additional file 1: Figures S13, S14, respectively).
Muscle inflammation
Inflammatory cytokines
In the 35-week cohort of mice, a significant rise in both 
TNF-α and IL-6 protein levels were seen in the gastroc-
nemius of U animals compared to non-exposed controls, 
whereas no significant differences were observed in the 
diaphragm (Fig. 14a, b).
Markers of proteolysis in muscles
All the analyses of proteolytic systems were carried out in 
the 35-week cohort mice. Protein levels of the following 
proteolytic markers: total protein ubiquitination, ubiq-
uitin-conjugating E214K, MURF-1, and calpain-1 did not 
significantly differ among the study groups in either time-
cohorts (Fig. 15a–d; Additional file 1: Figures S15–18).
Markers of autophagy in muscles
All the analyses of muscle autophagy were carried out 
in the 35-week cohort mice. Protein levels of P62 were 
only significantly increased in the diaphragm of U mice 
compared to non-exposed controls (Fig. 16a; Additional 
file 1: Figure S19). In U and E–U mice, protein levels of 
beclin-1 and LC3 were significantly increased in the limb 
muscle compared to the controls (Fig. 16b, c; Additional 
Fig. 6 Schematic representation of the distribution of the cross‑sectional areas of the muscle fibers in the diaphragm and gastrocnemius muscles 
in both 20‑ and 35‑week time cohorts of animals (a–d, respectively). Values of cross‑sectional areas in the control mice are represented in light grey 
bars, while those detected in U and E–U animals are represented in dark grey and black respectively in all the histograms (a–d)
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file 1: Figures S20, S21). Furthermore, in the diaphragm, 
LC3 levels were also significantly greater in U and E–U 
mice than in the controls (Fig. 16c; Additional file 1: Fig-
ure S21).
Discussion
Whole body weight and muscle mass loss and the profile 
of alterations in muscle fiber phenotype and molecular 
markers of protein metabolism were in general similar 
in the respiratory and limb muscles of both groups of 
mice bearing the lung tumors regardless of underlying 
emphysema. Interestingly, when the relative individual 
muscle mass to total body weight parameter was esti-
mated in all the experimental groups, significant reduc-
tions were observed in diaphragm (both time-cohorts) 
and gastrocnemius (35-week cohort) only in U mice 
compared to the non-exposed controls. Body weight gain 
was significantly more reduced in E–U mice, especially in 
those of the 35-week cohort. Indeed, actual body weights 
were of similar values at the end of both 35- and 24-week 
periods, while control and U animals were of larger size 
at 35-week than at 24-week time-points. In addition, the 
Fig. 7 a Mean values and standard deviation of the percentage of abnormal fraction (white bars), cellular inflammation (grey bars) and inter‑
nal nuclei (black bars) in the diaphragm muscle of the 20‑week cohort animals. Statistical significance is represented as follows: *p ≤ 0.05 and 
***p ≤ 0.001 between any of the intervention groups (U and E–U) and control mice. b Mean values and standard deviation of the percentage of 
abnormal fraction (white bars), cellular inflammation (grey bars) and internal nuclei (black bars) in the gastrocnemius muscle of 20‑week cohort 
animals. Statistical significance is represented as follows: n.s.: non‑significant and *p ≤ 0.05 between any of the intervention groups (U and E–U) 
and control mice. c Representative examples of muscle structural abnormalities in diaphragm of 20‑week cohort animals (calibration bar 100 μm). A 
representative image of muscles in U group (right top image), in which black arrows point towards inflammatory cells, and a representative image of 
muscles in E–U group (right bottom image), in which black arrows point towards inflammatory cells and internal nuclei. d Representative examples 
of muscle structural abnormalities in gastrocnemius of 20‑week cohort animals (calibration bar 100 μm). A representative image of muscles in U 
group (right top image), in which black arrows point towards inflammatory cells, and a representative image of E–U group (right bottom image), in 
which black arrows point towards internal nuclei. E–U elastase–urethane, U urethane
Page 13 of 23Salazar‑Degracia et al. J Transl Med  (2016) 14:244 
cross-sectional area of slow- and fast-twitch muscle fib-
ers was significantly smaller in both diaphragm and gas-
trocnemius muscles of the tumor-bearing animals, with 
a significantly larger reduction in the respiratory muscle 
of the E–U groups in both time-cohorts. In the investiga-
tion, other interesting findings were the rise in the num-
ber of total muscle abnormalities, including increased 
inflammatory cells in diaphragm of both time-cohorts, 
and apoptotic nuclei counts in both muscles studied of 
the tumor-bearing mice (24- and 35-week time cohorts) 
regardless of emphysema along with changes in the 
expression of biological markers involved in muscle mass 
maintenance and metabolism, which are discussed below.
In the present study, the size of slow- and fast-twitch 
fibers was significantly reduced in the respiratory and 
limb muscles of U and E–U mice of both time-cohorts. 
These findings are in agreement with those reported in 
previous investigations, in which the cross-sectional area 
of both types of fibers were also significantly smaller 
in diaphragm and gastrocnemius muscles of different 
experimental models of muscle wasting such as chronic 
heart failure [6] and cancer-induced cachexia [6–8, 11]. 
Fig. 8 a Mean values and standard deviation of the percentage of abnormal fraction (white bars), cellular inflammation (grey bars) and internal 
nuclei (black bars) in the diaphragm muscle of 35‑week cohort animals. Statistical significance is represented as follows: **p ≤ 0.01 and ***p ≤ 0.001 
between any of the intervention groups (U and E–U) and control mice. b Mean values and standard deviation of the percentage of abnormal 
fraction (white bars), cellular inflammation (grey bars) and internal nuclei (black bars) in the gastrocnemius muscle of 35‑week cohort. Statistical 
significance is represented as follows: *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 between any of the intervention groups (U and E–U) and control mice. 
c Representative examples of muscle structural abnormalities in diaphragm of 35‑week cohort animals (calibration bar 100 μm). A representative 
image of muscles in U group (right top image), in which black arrows point towards internal nuclei, and a representative image of E–U group (right 
bottom image), in which black arrows point towards inflammatory cells and internal nuclei. d Representative examples of muscle structural abnor‑
malities in gastrocnemius of 35‑week cohort animals (calibration bar 100 μm). A representative image of muscles in U group (right top image), in 
which black arrows point towards internal nuclei and a representative image of E–U group (right bottom image), in which black arrows point towards 
inflammatory cells and internal nuclei. E–U elastase–urethane, U urethane
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Collectively, these results suggest that the process of 
muscle mass loss associated with chronic conditions 
equally affects both types of muscles in experimental 
models of muscle wasting [6–8, 47]. It should also be 
highlighted that when the parameter muscle weight to 
total body weight was analyzed, a significant decline in 
muscle mass was only seen in U group, but not in E–U 
mice. This is likely due to the fact that the animals in the 
latter group were of smaller size as determined by their 
total body weight, thus implying that muscle mass was 
relatively better preserved in E–U mice compared to U 
rodents. It is possible that hypoxia, although not meas-
ured in the study, may have limited the growth of mice in 
the E–U group (underlying emphysema) throughout time 
as shown to occur in other models [48, 49]. Nonetheless, 
we believe that elucidation of the mechanisms accounting 
for this observation are beyond the scope of the current 
study, as muscle mass was, indeed, reduced in both types 
of muscles in U and E–U groups in the two time-cohorts. 
On the other hand, the decrease observed in muscle mass 
loss was probably not due to a decline in food intake as 
no evident reductions in this parameter or even in the 
physical activity of the animals were detected during 
the study period, despite not having been specifically 
quantified in the investigation. In keeping with the pre-
sent findings, patients with muscle wasting and cachexia 
related to chronic conditions also exhibited muscle atro-
phy, especially of the fast-twitch fibers in their lower 
Fig. 9 a Mean values and standard deviation of the percentage of positively stained nuclei for the TUNEL assay in diaphragm (white bars) and 
gastrocnemius (black bars) muscles of the 20‑week cohort of animals. Statistical significance is represented as follows: **p ≤ 0.01 and ***p ≤ 0.001 
between any of the intervention groups (U and E–U) and control mice. b Representative examples of positively nuclei (red arrows) stained for the 
TUNEL assay in the diaphragm (top panel) and gastrocnemius (bottom panel) muscles of the 20‑week cohort of the different study groups of mice 
(calibration bar 100 μm)
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limb muscles [4, 16, 18]. These phenotypic features have 
also been shown in the quadriceps of elderly subjects, in 
whom the muscle fibers were more prone to experience 
reductions in their cross-sectional area [50–52].
Levels of proinflammatory cytokines (TNF-α and IL-6) 
that may mediate muscle wasting [13], although low, were 
significantly increased in the limb muscle of tumor-bear-
ing animals without underlying emphysema (U group). 
Furthermore, inflammatory cell counts significantly 
increased in both types of muscles of the 35-week cohort, 
as well as in the diaphragm of the 20-week cohort. These 
mechanisms may explain the relatively larger reduc-
tion in muscle mass observed in U group, especially the 
diaphragm.
Importantly, in both time-cohorts, the greatest reduc-
tion in the size of slow- and fast-twitch muscle fibers was 
achieved in the diaphragm of tumor-bearing mice, espe-
cially in those with underlying emphysema. Interestingly, 
the characteristic switch towards a more fatigue-resistant 
phenotype identified in the diaphragm of patients with 
advanced COPD [17, 29] was not observed in the respira-
tory muscle of the study animals. It is likely that a longer 
exposure to inspiratory loading is required in order to 
trigger a switch towards a more fatigue-resistant pheno-
type of the main respiratory muscle in mice. Enhanced 
protein catabolism as a result of the increased burden 
imposed by the underlying respiratory emphysematous 
condition (increased inspiratory loads) together with the 
Fig. 10 a Mean values and standard deviation of the percentage of positively stained nuclei for the TUNEL assay in diaphragm (white bars) and 
gastrocnemius (black bars) muscles of the 35‑week cohort of animals. Statistical significance is represented as follows: ***p ≤ 0.001 between any 
of the intervention groups (U and E–U) and control mice. b Representative examples of positively nuclei (red arrows) stained for the TUNEL assay in 
the diaphragm (top panel) and gastrocnemius (bottom panel) muscles of the 35‑week cohort of the different study groups of mice (calibration bar 
100 μm). E–U elastase–urethane, U urethane
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presence of the lung tumors, which further increase the 
respiratory loads, may explain the smaller cross-sectional 
area of the diaphragm fibers found in the muscle-wasted 
mice. In fact, protein levels of specific muscle proteins 
such as creatine kinase, MyHC and actin were signifi-
cantly reduced in the diaphragms of U and E–U mice 
in both time-cohorts. In the gastrocnemius, however, 
underlying emphysema did not further reduce the size 
of either slow- or fast-twitch muscle fibers in the cancer 
cachectic animals, and actin levels in the limb muscle 
of E–U mice were as high as those detected in the same 
muscles of control animals. Together these observations 
point towards a predominant systemic effect of car-
cinogenesis on muscle mass loss of both diaphragm and 
gastrocnemius in the urethane-exposed mice along with 
the local effects imposed by the emphysema-related res-
piratory loads in the diaphragm muscle.
A significant rise in several structural abnormalities 
such as inflammatory cell (especially the diaphragm) 
and internal nuclei counts was also observed in the dia-
phragm and gastrocnemius muscles of the tumor-bear-
ing mice in the two experimental groups of both study 
cohorts. The number of apoptotic nuclei was also sig-
nificantly increased in the respiratory and limb muscles 
of the same animals in both experimental groups of the 
two study cohorts. Collectively, these findings are totally 
in line with those reported in previous investigations, in 
which the levels of structural abnormalities and those of 
Fig. 11 a Mean values and standard deviation of skeletal muscle actin, in diaphragm (white bars) and gastrocnemius (black bars) muscles as 
measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant and ***p ≤ 0.001 between any of the interven‑
tion groups (U and E–U) and control mice. b Mean values and standard deviation of MyHC, in diaphragm (white bars) and gastrocnemius (black 
bars) muscles as measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant, **p ≤ 0.01, and ***p ≤ 0.001 
between any of the intervention groups (U and E–U) and control mice. c Mean values and standard deviation of creatine kinase (CK), in diaphragm 
(white bars) and gastrocnemius (black bars) muscles as measured by optical densities. Statistical significance is represented as follows: *p ≤ 0.05 and 
***p ≤ 0.001 between any of the intervention groups (U and E–U) and control mice. d Mean values and standard deviation of carbonic anhydrase‑3, 
in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured by optical densities. Statistical significance is represented as follows: 
n.s.: non‑significant and ***p ≤ 0.001 between any of the intervention groups (U and E–U) and control mice. a.u. arbitrary units, E–U elastase–ure‑
thane, MyHC myosin heavy chain, OD optical densities, U urethane
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TUNEL-positive nuclei were also detected in the respira-
tory and peripheral muscles of animals with muscle wast-
ing associated with several conditions [6–8], as well as 
in patients with COPD [4, 44] and LC [4]. These results 
also point towards the existence of a damage-repair 
mechanism within the myofibers of the target muscles 
in response to muscle mass loss, which seemed to have 
taken place in the respiratory and peripheral muscles in 
a similar fashion. Indeed, the increase in the numbers of 
inflammatory cells and internal nuclei imply the exist-
ence of an underlying repair process following injury of 
the mouse skeletal muscles within the frame of LC- and 
emphysema-induced muscle wasting.
Additionally, from a molecular standpoint, alterations 
in the levels of muscle regeneration and metabolism, 
namely myogenin, PPAR-α and PPAR-γ were also seen in 
the diaphragm and gastrocnemius of tumor-bearing mice. 
PPARs are strong regulators of muscle metabolism and 
mitochondrial biogenesis [53, 54], and are also involved 
in the fiber type shift towards a more resistant phenotype 
[55]. PPARs may also underlie signaling of muscle atro-
phy in cachectic conditions [19]. In the current study, 
Fig. 12 a Mean values and standard deviation of myogenin, in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured by 
optical densities. Statistical significance is represented as follows: n.s.: non‑significant and ***p ≤ 0.001 between any of the intervention groups (U 
and E–U) and control mice. b Mean values and standard deviation of PPAR‑α, in diaphragm (white bars) and gastrocnemius (black bars) muscles as 
measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant, *p ≤ 0.05 and ***p ≤ 0.001 between any of the 
intervention groups (U and E–U) and control mice. c Mean values and standard deviation of PPAR‑gamma, in diaphragm (white bars) and gastroc‑
nemius (black bars) muscles as measured by optical densities. Statistical significance is represented as follows: *p ≤ 0.05 and ***p ≤ 0.001 between 
any of the intervention groups (U and E–U) and control mice. d Mean values and standard deviation of PGC‑1α, in diaphragm (white bars) and 
gastrocnemius (black bars) muscles as measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant between 
any of the intervention groups (U and E–U) and control mice. a.u. arbitrary units, E–U elastase–urethane, OD optical densities, PPAR- peroxisome 
proliferator‑activated receptor alpha; PPAR- peroxisome proliferator‑activated receptor gamma, PGC-1 peroxisome proliferator‑activated receptor 
gamma coactivator‑1α, U urethane
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levels of PPAR-α were significantly decreased in the dia-
phragm of tumor-bearing mice regardless of emphysema, 
while a decline in PPAR-gamma levels was identified in 
both respiratory and limb muscles of the same groups 
of animals. These are interesting observations that are 
in accordance with a previous investigation, in which 
similar findings were also reported in the vastus later-
alis of patients with severe COPD, especially in those 
with muscle wasting [19]. Taken together, it is possible to 
conclude that PPARs underlie atrophy signaling in both 
Fig. 13 a Mean values and standard deviation of MDA, in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured by optical 
densities. Statistical significance is represented as follows: (i) n.s.: non‑significant and **p ≤ 0.01 between any of the intervention groups (U and E–U) 
and control mice. b Mean values and standard deviation of SOD1, in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured 
by optical densities. Statistical significance is represented as follows: n.s.: non‑significant and ***p ≤ 0.001 between any of the intervention groups 
(U and E–U) and control mice. c Mean values and standard deviation of SOD2, in diaphragm (white bars) and gastrocnemius (black bars) muscles 
as measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant, **p ≤ 0.01 and ***p ≤ 0.001 between any of 
the intervention groups (U and E–U) and control mice. d Mean values and standard deviation of catalase, in diaphragm (white bars) and gastrocne‑
mius (black bars) muscles as measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant and ***p ≤ 0.001 
between any of the intervention groups (U and E–U) and control mice. a.u. arbitrary units, E–U elastase–urethane, MDA malondialdehyde, OD opti‑
cal densities, SOD1 superoxide dismutase isoform 1, SOD2 superoxide dismutase isoform 2, U urethane
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respiratory and peripheral muscles, at least in these mod-
els of cachexia. Nevertheless, levels of proteolytic mark-
ers (ubiquitin–proteasome system) were not modified in 
the muscles of either U or E–U mice in any of the study 
cohorts compared to non-exposed controls. The rise in 
apoptotic nuclei and autophagy markers were probably 
the most relevant contributors to the atrophy observed in 
the myofibers of the diaphragm and gastrocnemius mus-
cles of the cachectic mice in both time-cohorts as was 
also shown to occur in previous studies [6–8].
Levels of protein oxidation were significantly increased 
in the gastrocnemius muscle of E–U cachectic mice, but 
not in U animals. These results are in line with those 
reported in our previous study, in which protein oxida-
tion levels also increased in the muscles of mice with 
elastase-induced emphysema [9], as well as in other 
investigations conducted on COPD patients, in whom 
oxidative stress levels were also increased in their res-
piratory [17, 29] and limb muscles [4, 25–27, 31, 56–58]. 
Furthermore, in both experimental mouse groups, pro-
tein levels of mitochondrial SOD2 and catalase were sig-
nificantly decreased only in the gastrocnemius but not 
the diaphragm, while those of the cytosolic SOD1 were 
significantly increased. These results are partly in keep-
ing with those shown in the diaphragm of the elastase-
induced emphysema mice [9], and in those of the vastus 
lateralis of COPD patients, in whom SOD1 protein lev-
els were also increased [4]. The degree of muscle mass 
loss together with differences in the study models may 
account for the discrepancies observed in antioxidant 
enzyme levels among studies.
Study limitations
The current model of induction of emphysema has been 
well-validated in the literature as many publications 
are currently available in which elastase has been used 
to induce emphysema in animal models [59, 60]. In the 
present investigation, elastase was chosen as it induces a 
rapid onset of emphysema in the lungs. Indeed, emphy-
sema developed at a much earlier stage than did the 
tumors in the mouse lungs, and this was a major objec-
tive in the study. A limitation in the investigation was the 
lack of functional data from the study muscles. However, 
as the current investigation represents a first approach to 
confirm the main hypothesis, we believe that this is not a 
major limitation, since it has been clearly confirmed by 
the histological and molecular experiments conducted in 
the investigation that muscle mass loss and atrophy occur 
in both respiratory and limb muscles in this model of 
lung carcinogenesis-induced muscle wasting. Moreover, 
experimental mouse models of cancer-induced cachexia 
are not characterized by the loss of body and/or mus-
cle mass as shown to occur in actual patients, since the 
Fig. 14 a Mean values and standard deviation of TNF‑α in diaphragm 
(white bars) and gastrocnemius (black bars) muscles as measured by 
picogram per milliliter (pg/mL). Statistical significance is repre‑
sented as follows: n.s.: non‑significant and *p ≤ 0.05 between any 
of the intervention groups (U and E–U) and control mice. b Mean 
values and standard deviation of IL‑6 in diaphragm (white bars) and 
gastrocnemius (black bars) muscles as measured by picogram per 
milliliter (pg/mL). Statistical significance is represented as follows: n.s.: 
non‑significant and ***p ≤ 0.001 between any of the intervention 
groups (U and E–U) and control mice. E–U elastase–urethane, IL-6 
interleukin‑6, TNF- tumor necrosis factor‑alpha, U urethane
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animals are still growing. Therefore, we believe that the 
reduction in both body weight gain and muscle sizes at 
the end of study protocol were the variables that best 
represented the decrease in muscle mass observed in the 
tumor-bearing animals with and without emphysema. 
Indeed, this is a general limitation in any animal model of 
cachexia and muscle wasting.
Conclusions
In this mouse model of lung carcinogenesis with and 
without emphysema, reduced body weight gain, and 
muscle mass loss and atrophy were indeed observed in 
the respiratory and limb muscles of the animals after 
20- and 35-week exposure times. In the mice, the pro-
cess of muscle wasting was characterized by a rise in the 
number of inflammatory cells, internal nuclei, apoptotic 
nuclei, and autophagy markers, but not proteolysis, while 
a decrease in the content of contractile proteins, creatine 
kinase, antioxidant enzymes, and PPARs was observed in 
a similar fashion in both respiratory and limb muscles. 
Nevertheless, underlying emphysema induced a larger 
reduction in the size of slow- and fast-twitch fibers in the 
diaphragm of tumor-bearing mice probably as a result of 
the greater inspiratory burden imposed onto this muscle. 
Fig. 15 a Mean values and standard deviation of total protein ubiquitination in diaphragm (white bars) and gastrocnemius (black bars) muscles 
as measured by optical densities. Statistical significance is represented as follows: (i) n.s.: non‑significant between any of the intervention groups 
(U and E–U) and control mice. b Mean values and standard deviation of E214K, in diaphragm (white bars) and gastrocnemius (black bars) muscles 
as measured by optical densities. Statistical significance is represented as follows: n.s.: non‑significant any of the intervention groups (U and E–U) 
and control mice. c Mean values and standard deviation of MURF‑1, in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured 
by optical densities. Statistical significance is represented as follows: n.s.: non‑significant between any of the intervention groups (U and E–U) and 
control mice. d Mean values and standard deviation of calpain‑1, in diaphragm (white bars) and gastrocnemius (black bars) muscles as measured 
by optical densities. Statistical significance is represented as follows: n.s.: non‑significant between any of the intervention groups (U and E–U) and 
control mice. a.u. arbitrary units, E–U elastase–urethane, E214k ubiquitin‑conjugating enzyme E2 (14k), MURF-1 muscle ring finger protein 1, OD opti‑
cal densities, U urethane
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These findings should be taken into consideration when 
evaluating muscle wasting in patients with lung cancer 
cachexia with and without underlying emphysema.
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